bupivacaine S50:R50 plus 8% glucose — Competitive Intelligence Brief

bupivacaine S50:R50 plus 8% glucose (bupivacaine S50:R50 plus 8% glucose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia.

phase 3 Local anesthetic Voltage-gated sodium channels Anesthesia Small molecule

Target snapshot

bupivacaine S50:R50 plus 8% glucose (bupivacaine S50:R50 plus 8% glucose) — Cristália Produtos Químicos Farmacêuticos Ltda.. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupivacaine S50:R50 plus 8% glucose TARGET	bupivacaine S50:R50 plus 8% glucose	Cristália Produtos Químicos Farmacêuticos Ltda.	phase 3	Local anesthetic	Voltage-gated sodium channels
Bupivacaine and Fentanyl	Bupivacaine and Fentanyl	Bnai Zion Medical Center	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl)
oral suzetrigine	oral suzetrigine	University of Louisville	marketed	Selective sodium channel blocker	Voltage-gated sodium channels (Nav)
Oral Zonisamide Therapy	Oral Zonisamide Therapy	Affiliated Hospital of Nantong University	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Bupivacaine Hydrochloride combined with dexamethasone	Bupivacaine Hydrochloride combined with dexamethasone	Zhejiang Cancer Hospital	marketed	Local anesthetic with corticosteroid adjuvant	Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
Bupivacaine 20cc	Bupivacaine 20cc	Hospital for Special Surgery, New York	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine Digital Block	Bupivacaine Digital Block	University of California, San Francisco	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class